T-Ray Science, Inc., a medical device company committed to commercializing innovative systems for the early detection of cancer announces that shareholders approved a change of the name of the Company to Verisante Technology, Inc.
Global Cancer Consortium
Hunting Disease In The Dark: MEDomics Seeks to Treat Mitochondrial Disease Before It Occurs
The core theory behind preventative medicine is almost psychic. To stop a disease from wielding its mighty weapons before it occurs is based on foreknowledge of a patient’s susceptibility to the illness.
ADVENTRX Pharmaceuticals Takes the Next Step In Approval of ANX-530
ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX), with its leading innovations in anti-cancer drug development has just announced that they have been successful in sending their ANX-530 (Exelbine) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011.
Oncology Panel Selected in OneMedForum SF 2011
Over 500,000 people will die from cancer in the United States this year. There are many companies developing diagnostics for early detection and advanced therapies to address the various types of cancer.
NYSSA Announces Presenter List for Upcoming Biotech Conference
The New York Society of Security Analysts, a leading forum for the investment community, recently announced the presenter list for its 14th Annual Biotech and Specialty Pharma Conference.
Brean Murray, Carret & Co. Host 2010 China Growth Conference
The Chinese market is booming and everyone wants a piece of the pie. China is not only the world’s second largest economy after the United States by purchasing power parity but is also the world’s fastest-growing major economy, with average growth rates of 10% for the past 30 years.
Blood Tests Can Enable Early Cancer Diagnosis
Scientists have yet to find the magic cure for cancer, but they may have found a way to beat it at its own game.
Molecular Diagnostics a Natural Fit for Breast Cancer
The growing global incidence of breast cancer has led to an increased demand for molecular diagnostics tests that aid in diagnosing breast cancer.
